FDA Revises Data Requirements for Huntington's Disease Gene Therapy Application

The U.S. Food and Drug Administration has indicated a willingness to consider three-year data from uniQure's Phase I/II study as the primary basis for a Biologics License Application for its Huntington's disease gene therapy, AMT-130. This marks a positive shift from the FDA's previous stance, which had deemed earlier-stage data insufficient. The updated guidance could potentially accelerate the regulatory pathway for this important treatment.